Unexpected borderline malignant and malignant smooth muscle cell tumors of the uterine corpus in women treated with LH-RH analogues.
In this report, two cases of uterine smooth muscle cell tumors, one of uncertain malignant potential and one clearly malignant, are described in women treated for prolonged periods with luteinizing hormone-releasing hormone (LH-RH) analogues. Due to lengthy monitoring of LH-RH therapy, surgical intervention and histologic classification of these tumors was late in the course of disease, resulting in a delay in definite treatment. The risk to these women is discussed. The effects of LH-RH analogue therapy on fibroids is reviewed. Suggestions are put forward for monitoring LH-RH analogue therapy.
Wauters
C C
CC
Department of Pathology, Diagnostic Centre SSDZ, Delft, The Netherlands.
Ter Harmsel
B W
BW
Hermans
M P
MP
Smedts
F
F
D000328:Adult; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D008875:Middle Aged; D012307:Risk Factors; D018235:Smooth Muscle Tumor / Q000139:chemically induced*; D014594:Uterine Neoplasms / Q000139:chemically induced*
D007987:Gonadotropin-Releasing Hormone